Latest News
From the Journals
Parkinson’s patients can lose swimming ability after deep brain stimulation
Ability returned within 30 minutes of turning off the stimulator, and loss of ability recurred within 30 minutes of resuming stimulation.
Literature Review
Antibiotic use may increase the risk of Parkinson’s disease
Use of antianaerobic or tetracycline antimicrobials may be associated with the later development of Parkinson’s disease.
Literature Review
Trial finds three drugs equally effective for established status epilepticus
Randomized study of fosphenytoin, valproate, and levetiracetam informs management of benzodiazepine-refractory disease.
Feature
CMS announces application process for Direct Contracting model
Letters of intent to participate are due by Dec. 10.
Conference Coverage
ACGME deepening its commitment to physician well-being, leader says
NEW ORLEANS – Positive social relationships with others are crucial to joy and well-being in the practice of...
Literature Review
‘Remarkable’ seizure-free rates seen with adjunctive cenobamate
During a trial of the recently approved drug, investigators lowered the starting dose and slowed the rate of up-titration to address a risk of...
Conference Coverage
Late-onset MS is often more severe than earlier-onset MS
ST. LOUIS – Late-onset MS often has faster accrual of disability and might require different treatment options.
From the Journals
‘Brain enhancement’ supplements sold online may illegally contain piracetam
So-called cognitive enhancement supplements sold online may contain high doses of the nootropic drug piracetam.
From the Journals
Researchers describe first cases of episodic visual snow associated with migraine
A series of migraine patients with episodic visual snow makes case for a condition that is distinct from visual snow syndrome.
Conference Coverage
Baseline subtypes predict dementia and death in patients with Parkinson’s disease
ST. LOUIS – Clinicians should assess cognitive and psychiatric symptoms at baseline.
FDA/CDC
FDA okays cenobamate (Xcopri) for focal epilepsy
Every story needs a teaser. Must differ from the headline. Meeting stories need a dateline. 150 characters or fewer.